SCHEMBL15210341

SCHEMBL15210341

CCn1cc(-c2ccnc3cc(-c4cc(C(N)=O)ccc4OC)oc23)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 10/20 0.45
SIK1 P57059 9/20 0.45
SIK2 Q9H0K1 9/20 0.45
SIK3 Q9Y2K2 9/20 0.45
ABL1 P00519 8/20 0.45
LYN P07948 8/20 0.45
TGFBR1 P36897 8/20 0.45
TGFBR2 P37173 8/20 0.45
PRKAB2 O43741 7/20 0.45
PRKAG1 P54619 7/20 0.45
PRKAA1 Q13131 7/20 0.45
SYK P43405 1/20 0.41
MAPK1 P28482 1/20 0.38
MKNK1 Q9BUB5 1/20 0.37
MKNK2 Q9HBH9 1/20 0.37
HSP90AA1 P07900 2/20 0.37
FLT4 P35916 2/20 0.36
KDR P35968 2/20 0.36
FLT1 P17948 1/20 0.36
PDGFRB P09619 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15210384 0.83 MAPK1 (0.43) MAPK1MKNK1MKNK2CHEK1CHEK2
SCHEMBL15212570 0.80 MKNK1 (0.42) MAPK1MKNK1MKNK2FLT4KDR
SCHEMBL15210434 0.79 CAMKK2 (0.39) MAPK1MKNK1MKNK2FLT3CHEK1
SCHEMBL15210462 0.78 CAMKK2 (0.42) ABL1LYNMAPK1MKNK1MKNK2
SCHEMBL15210343 0.77 GAA (0.41) MAPK1MKNK1MKNK2KDRCHEK1
SCHEMBL15210438 0.77 SLC9A1 (0.43) MAPK1MKNK1MKNK2CHEK1CHEK2
SCHEMBL724725 0.77 PRKAB2 (0.42) CSF1RSIK1SIK2SIK3ABL1
SCHEMBL15210498 0.77 AR (0.38) SYKMAPK1MKNK1MKNK2FLT4
SCHEMBL15210587 0.76 AR (0.44) MAPK1MKNK1MKNK2FLT3CHEK1
SCHEMBL15210505 0.76 CAMKK2 (0.38) SYKMAPK1MKNK1MKNK2CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2817313-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-07 EP claimed
EP-2817313-A1 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2014-12-31 EP claimed
WO-2013124025-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-29 WO claimed
EP-2817313-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-07 EP disclosed
US-20150038527-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-02-05 US disclosed
EP-2817313-A1 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2014-12-31 EP disclosed
WO-2013124025-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038527-A1 FUROPYRIDINE DERIVATIVES SYK, LYN, BTK CSF1R 107/4885SIK1 1236/4885SIK2 1268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.